Trial · NCT05200312
A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
NCT05200312, Phase 2, Unknown, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma. Trials, record NCT05200312. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05200312
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma
- NCT number
- NCT05200312
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 36 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
- Interventions
- Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent)
- First posted
- 2022-01-20
- Last updated
- 2022-03-11
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response rate after six cycles of ZR2-CHOP | at the end of 6 cycles(each cycle is 21 days) | Complete response rate will be assessed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) according to 2014 Lugano Criteria. |
| Secondary | Progression-Free Survival (PFS) two years follow-up | At 2 years | PFS was defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first. Responses were based on 2014 Lugano Criteria. |
| Secondary | Overall survival (OS) two years follow-up | At 2 years | Overall survival was defined as the duration from the date of randomization to the date of the participant's death. Median Overall Survival was estimated by using the Kaplan-Meier method. |
| Secondary | Circulating tumor Deoxyribonucleic Acid (ctDNA) clearance rate | Baseline (At initial start), at the end of 2,4 ,6 cycles(each cycle is 21 days) | ctDNA will be measured at baseline and after 2, 4, 6 cycles of ZR2-CHOP |
| Secondary | Overall response rate after six cycles of ZR2-CHOP | at the end of 6 cycles(each cycle is 21 days) | Overall response rate will be assessed by FDG-PET/CT or CT scan according to 2014 Lugano Criteria. |
| Secondary | Overall response rate after two, four cycles of ZR2-CHOP | at the end of 2,4 cycles(each cycle is 21 days) | Overall response rate will be assessed by FDG-PET/CT according to 2014 Lugano Criteria. |
| Secondary | Complete response rate after two, four cycles of ZR2-CHOP | at the end of 2,4 cycles(each cycle is 21 days) | Overall response rate will be assessed by FDG-PET/CT according to 2014 Lugano Criteria. |
| Secondary | Incidence of adverse events | At 2 years | Toxicities will be summarized by grade and by their relationship to treatment according to CTCAE (version 5.0). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41136989 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05200312
GET https://conductscience.org/api/trials/v1/NCT05200312/registered